I do not disagree... Wonder how much LEO CEO change played into "change in course"? ... seems to me LEO is more focused on dermatology than critical care
You do agree numerous studies show ATIII as promising for DIC and ATIII is used for DIC in Japan and some countries in Europe?
>> Hoping against hope LFB can get European ATryn sales moving.
I just regurgitated some goat cheese! Thanks, Dew :-)
Red Cox has NOT been forthcoming! I often wondered why they presented often at the Mandarin Oriental on the French Riviera. Clandestine meetings with LFB?? Distant cousins?? :-)
Not sure what that is in the field of science other than I guess the stench of inuendo. Nobody on this board, including a guy who has "dumped" all his shares all the while criticizing the company as the price fell, has any knowledge of why LEO is turning the trials over to LFB.
I did ask Rustyboy a couple of weeks ago about this and he said he had been told by management that it had something to do with LEO being under some charitable trust or some such. I can tell you and I feel certain both biopearl and MBT would feel the same way that the pathophysiology is certainly compatable with AT possibly working in DIC and that the KS subset AT without heparin is reasonably compelling. Thats about the best you can do when it comes to these things.
Market Data 
Markets 
AI
